Sionna Therapeutics, Inc. (SION)
NASDAQ: SION · Real-Time Price · USD
41.77
+0.98 (2.40%)
At close: Jan 22, 2026, 4:00 PM EST
42.31
+0.54 (1.29%)
After-hours: Jan 22, 2026, 6:54 PM EST
Sionna Therapeutics Employees
Sionna Therapeutics had 41 employees as of December 31, 2024. The number of employees increased by 13 or 46.43% compared to the previous year.
Employees
41
Change (1Y)
13
Growth (1Y)
46.43%
Revenue / Employee
n/a
Profits / Employee
-$1,723,805
Market Cap
1.86B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 41 | 13 | 46.43% |
| Dec 31, 2023 | 28 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SION News
- 9 days ago - Sionna Therapeutics, Inc. (SION) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 17 days ago - Sionna Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Sionna Therapeutics, Inc. (SION) Presents at Citi Annual Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 2 months ago - Sionna Therapeutics to Participate in Upcoming December Investor Conferences - GlobeNewsWire
- 2 months ago - Sionna Therapeutics Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 2 months ago - Sionna Therapeutics to Participate in Upcoming November Investor Conferences - GlobeNewsWire
- 3 months ago - Sionna Therapeutics Announces Presentation of SION-719 and SION-451 Phase 1 Data and Poster of New Preclinical Data on the Impact of NBD1 Stabilizers on F508del-CFTR Half-Life at the 2025 North American Cystic Fibrosis Conference - GlobeNewsWire
- 3 months ago - Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis - GlobeNewsWire